Literature DB >> 20709565

Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy.

A A Aaldriks1, E Maartense, S le Cessie, E J Giltay, H A C M Verlaan, L G M van der Geest, W M Kloosterman-Boele, M T Peters-Dijkshoorn, B A Blansjaar, H W van Schaick, J W R Nortier.   

Abstract

INTRODUCTION: Comprehensive geriatric assessment (CGA) gives useful information on the functional status of older cancer patients. However, its meaning for a proper selection of elderly patients before chemotherapy and, even more important, the influence of chemotherapy on the outcome of geriatric assessment is unknown.
METHODS: 202 cancer patients, for whom an indication for chemotherapy was made by the medical oncologist, underwent a GA before start of chemotherapy by Mini Nutritional Assessment (MNA), Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), Groningen Frailty Index (GFI) and Mini Mental State Examination (MMSE). After completion of a minimum of four cycles of chemotherapy or at 6 months after the start of chemotherapy the GFI and MMSE assessment was repeated.
RESULTS: Frailty was shown in 10% of patients by means of MMSE, 32% by MNA, 37% by GFI and in 15% by IQCODE. Compared to patients who received 4 or more cycles of chemotherapy, the MNA and MMSE scores were significantly lower for patients treated with less than 4 cycles (p = 0.001 and p = 0.04 respectively). The mortality rate after start of chemotherapy was increased for patients with low MNA and high GFI scores with hazard ratios of 2.19 (95% confidence interval [CI]: 1.42-3.39; p < 0.001) and 1.80 (95% CI: 1.17-2.78; p = 0.007), respectively. After adjusting for sex, age, purpose of chemotherapy and type of malignancy these hazard ratios remained significant (p < 0.001 and p = 0.004), respectively. Finally, for the 51 patients who underwent repeated post-chemotherapy evaluation by GFI and MMSE, a statistically significant deterioration for the MMSE (p = 0.041) was found but not for the GFI.
CONCLUSIONS: Both inferior MNA and MMSE scores increased the probability not to complete chemotherapy. Also, an inferior score for MNA and GFI showed an increased mortality risk after the start of chemotherapy. The mean MMSE score worsened significantly during chemotherapy.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709565     DOI: 10.1016/j.critrevonc.2010.05.009

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  37 in total

1.  Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study.

Authors:  Marie Laurent; Elena Paillaud; Christophe Tournigand; Philippe Caillet; Aurélie Le Thuaut; Jean-Léon Lagrange; Olivier Beauchet; Hélène Vincent; Muriel Carvahlo-Verlinde; Stéphane Culine; Sylvie Bastuji-Garin; Florence Canouï-Poitrine
Journal:  Oncologist       Date:  2014-02-25

2.  Chemotoxicity recurrence in older patients: Risk factors and effectiveness of preventive strategies-a prospective study.

Authors:  Martine Extermann; Richard R Reich; Marina Sehovic
Journal:  Cancer       Date:  2015-05-29       Impact factor: 6.860

Review 3.  The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer.

Authors:  Marije E Hamaker; Alinda G Vos; Carolien H Smorenburg; Sophia E de Rooij; Barbara C van Munster
Journal:  Oncologist       Date:  2012-08-31

4.  Changes in the Use of Comprehensive Geriatric Assessment in Clinical Trials for Older Patients with Cancer over Time.

Authors:  Olivia Le Saux; Claire Falandry; Hui K Gan; Benoit You; Gilles Freyer; Julien Péron
Journal:  Oncologist       Date:  2019-02-01

5.  Models of Care in Geriatric Oncology.

Authors:  A Magnuson; W Dale; S Mohile
Journal:  Curr Geriatr Rep       Date:  2014-09

Review 6.  Determining chemotherapy tolerance in older patients with cancer.

Authors:  Jerome Kim; Arti Hurria
Journal:  J Natl Compr Canc Netw       Date:  2013-12-01       Impact factor: 11.908

7.  Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old.

Authors:  Yanfeng Liu; Haibo Liu; Hausheng Liu; Pengcheng He; Jing Li; Xin Liu; Limei Chen; Mengchang Wang; Jiejing Xi; Huaiyu Wang; Haitao Zhang; Ying Zhu; Wei Zhu; Jing Ning; Caili Guo; Chunhong Sun; Mei Zhang
Journal:  Oncol Lett       Date:  2016-11-02       Impact factor: 2.967

8.  Geriatric assessment factors are associated with mortality after hospitalization in older adults with cancer.

Authors:  Sushma Jonna; Leslie Chiang; Jingxia Liu; Maria B Carroll; Kellie Flood; Tanya M Wildes
Journal:  Support Care Cancer       Date:  2016-07-27       Impact factor: 3.603

9.  Doublet chemotherapy in the elderly patient with ovarian cancer.

Authors:  Min Y Teo; Derek G Power; William P Tew; Stuart M Lichtman
Journal:  Oncologist       Date:  2012-08-22

Review 10.  Incorporating Geriatric Medicine Providers into the Care of the Older Adult with Cancer.

Authors:  Allison Magnuson; Beverly Canin; G J van Londen; Beatrice Edwards; Pamela Bakalarski; Ira Parker
Journal:  Curr Oncol Rep       Date:  2016-11       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.